Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Dow
Covington
Julphar
Healthtrust
US Department of Justice
UBS
Farmers Insurance
Fuji
Deloitte

Generated: October 21, 2017

DrugPatentWatch Database Preview

Mylan Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for MYLAN PHARMS INC, and when can generic versions of MYLAN PHARMS INC drugs launch?

MYLAN PHARMS INC has two hundred and forty approved drugs.

There are twelve US patents protecting MYLAN PHARMS INC drugs. There are twenty-nine tentative approvals on MYLAN PHARMS INC drugs.

There are two hundred and nineteen patent family members on MYLAN PHARMS INC drugs in forty countries and three hundred and forty-nine supplementary protection certificates in thirteen countries.

Summary for Applicant: Mylan Pharms Inc

International Patents:219
US Patents:12
Tradenames:196
Ingredients:186
NDAs:240
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc
VALSARTAN
valsartan
TABLET;ORAL090866-003Jan 5, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
GUANFACINE HYDROCHLORIDE
guanfacine hydrochloride
TABLET, EXTENDED RELEASE;ORAL202578-001Jun 2, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
ATORVASTATIN CALCIUM
atorvastatin calcium
TABLET;ORAL091226-001May 29, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
FOSAMPRENAVIR CALCIUM
fosamprenavir calcium
TABLET;ORAL204060-001Apr 15, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
ALPRAZOLAM
alprazolam
TABLET;ORAL074046-001Oct 19, 1993ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
TRETINOIN
tretinoin
GEL;TOPICAL202026-001Jul 17, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
DESLORATADINE
desloratadine
TABLET;ORAL078351-001Feb 10, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
FENOFIBRATE (MICRONIZED)
fenofibrate
CAPSULE;ORAL202676-001Oct 23, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
ZOLPIDEM TARTRATE
zolpidem tartrate
TABLET;ORAL078016-002Apr 23, 2007DISCNNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
ZONISAMIDE
zonisamide
CAPSULE;ORAL077647-003Dec 22, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Mylan Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Pharms Inc
ZOVIRAX
acyclovir
CAPSULE;ORAL018828-001Jan 25, 1985► Subscribe► Subscribe
Mylan Pharms Inc
MAXZIDE
hydrochlorothiazide; triamterene
TABLET;ORAL019129-001Oct 22, 1984► Subscribe► Subscribe
Mylan Pharms Inc
AVITA
tretinoin
CREAM;TOPICAL020404-003Jan 14, 1997► Subscribe► Subscribe
Mylan Pharms Inc
DENAVIR
penciclovir
CREAM;TOPICAL020629-001Sep 24, 1996► Subscribe► Subscribe
Mylan Pharms Inc
OLUX
clobetasol propionate
AEROSOL, FOAM;TOPICAL021142-001May 26, 2000► Subscribe► Subscribe
Mylan Pharms Inc
MAXZIDE-25
hydrochlorothiazide; triamterene
TABLET;ORAL019129-003May 13, 1988► Subscribe► Subscribe
Mylan Pharms Inc
DENAVIR
penciclovir
CREAM;TOPICAL020629-001Sep 24, 1996► Subscribe► Subscribe
Mylan Pharms Inc
ZOVIRAX
acyclovir
TABLET;ORAL020089-001Apr 30, 1991► Subscribe► Subscribe
Mylan Pharms Inc
MAXZIDE
hydrochlorothiazide; triamterene
TABLET;ORAL019129-001Oct 22, 1984► Subscribe► Subscribe
Mylan Pharms Inc
ZOVIRAX
acyclovir
TABLET;ORAL020089-002Apr 30, 1991► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for MYLAN PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
ketoconazole
Foam2%
EXTINA
7/30/2009
betamethasone valerate
Foam0.12%
LUXIQ
8/10/2007
clobetasol propionate
Topical Foam0.05%
OLUX
6/27/2005

Non-Orange Book Patents for Mylan Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,886,215 2-acetoxymethyl-4-halo-butyl-1-yl acetates► Subscribe
8,586,008Pharmaceutical foam► Subscribe
6,126,920 Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition► Subscribe
5,075,445 Guanine derivatives► Subscribe
6,573,378 Antiviral guanine derivatives► Subscribe
8,263,580Vitamin formulation► Subscribe
8,449,867Microemulsion and sub-micron emulsion process and compositions► Subscribe
9,486,394Pharmaceutical foam► Subscribe
9,492,384Microemulsion and sub-micron emulsion process and compositions► Subscribe
8,586,066Topical antifungal composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Mylan Pharms Inc Drugs

Country Document Number Estimated Expiration
Spain2447301► Subscribe
Canada1262899► Subscribe
Bulgaria61325► Subscribe
Australia9728898► Subscribe
Hungary228890► Subscribe
Canada2578594► Subscribe
Japan5612263► Subscribe
Austria253367► Subscribe
Israel169761► Subscribe
Ireland852307► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Mylan Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
128Luxembourg► SubscribePRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE
0677Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
/1999Austria► SubscribePRODUCT NAME: ''IRBESARTAN'' ZUSAMMEN MIT ''HYDROCHLOROTHIAZID''; REGISTRATION NO/DATE: EU/1/98/086/001 - EU/1/98/086/006 19981015
C/GB11/044United Kingdom► SubscribePRODUCT NAME: PALIPERIDONE PALMITATE; REGISTERED: UK EU/1/11/672/001 20110304; UK EU/1/11/672/002 20110304; UK EU/1/11/672/003 20110304; UK EU/1/11/672/004 20110304; UK EU/1/11/672/005 20110304; UK EU/1/11/672/006 20110304
C/GB98/047United Kingdom► SubscribePRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
00445Netherlands► SubscribePRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
C0011Belgium► SubscribePRODUCT NAME: RIZATRIPTAN BENZOAS EQ. RIZATRIPTAN; REGISTRATION NO/DATE: 922 IS 181 F 3 19981130; FIRST REGISTRATION: NL RVG 21815 19980211
C0050France► SubscribePRODUCT NAME: VALSARTAN; REGISTRATION NO/DATE IN FRANCE: NL 22077 DU 19970321; REGISTRATION NO/DATE AT EEC: 369830000 DU 19960513
2014 00037Denmark► SubscribePRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116
0048Netherlands► SubscribePRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NATL. REGISTRATION: RVG 21079 RVG 21080 19970925; FIRST REGISTRATION: PL 12619/0116 19970307
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Moodys
Cantor Fitzgerald
Julphar
US Army
US Department of Justice
Farmers Insurance
Cerilliant
Deloitte
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot